Abstract:Background Sodium-Glucose coTransporter 2 inhibitors (SGLT2i) medication is FDA approved for first-line guideline-directed medical therapy for the treatment of heart failure irrespective of diabetic status. Common examples of SGLT2i used include Empagliflozin and Dapagliflozin and the contraindications of these are GFR<30 with dapagliflozin, <20 with empagliflozin, type 1 diabetics, and lower SBP <95 to 100 mm Hg. The objective of our study is to determine if an inpatient cardiology consult and follow-up with a cardiologist outpatient had any association with the prescription of SGLT2i in heart failure patients, along with the readmission rates and mortality reduction in a community setting. Methods We retrospectively collected data from a Community Hospital for 4 months from May 20 to September 20’2022 for patients admitted with heart failure. Data collection and analysis for 474 patients were done using Excel, the chi-square test, and Python algorithms. The eligibility for SGLT2i was defined as any patient with the diagnosis of Heart failure with GFR>30ml/min/1.73m2. Results Our results revealed that only 4%(19/474) of the patients eligible for SGLT2i were receiving the medication. Out of the list of 19 patients prescribed SGLT2i, it was a home medication for 16 and started in the Hospital for 3 patients. Out of the list of patients who were prescribed SGLT2i, 63%(12/19) had an inpatient cardiology consult and 57%(11/19) of patients had an outpatient cardiologist. 46.3%(211/455) of patients who were not on SGLT2i had been seen by a cardiologist inpatient but never on the medication. 25%(116/455) of patients who were not on the medication had an outpatient cardiologist. The chi-square test for outpatient cardiologist and inpatient cardiology consult revealed a p-value of 0.6 and 0.3 respectively. 100% of the patients on SGLT2i with GFR<30 and >45 had no readmission reported. 20% readmission rates were reported in patients with GFR 30-45 at <30 days. 0% mortality was reported in patients on SGLT2i with GFR< 30, in comparison to 0.4% in patients with GFR>45 and 1.6% in patients with GFR 30-45 and the study was statistically insignificant (p value-0.3). Conclusion We found no association to conclude that having an inpatient cardiology consult or follow-up with a cardiologist outpatient increases the chances of a patient with heart failure to be prescribed SGLT2i. The study does reproduce the reduction in readmission rates, hospitalization, and mortality rates as was demonstrated in large-scale trials confirming the utilization of this drug at a community level. The barriers associated with the nonprescription of the SGLT2i include the lack of awareness about its indications in both HFpEF and HFrEF, its contraindications, and the inconvenience associated with prescription in patients requiring prior authorization. Our Quality improvement project aimed at recognizing these barriers and introducing interventions including forming a dot phrase for documentation for patients admitted with the diagnosis of heart failure, initiating the prior authorization form if needed in the hospital.

Inpatient initiation of sodium-glucose cotransporter-2 inhibitors: the prescribing learning curve

In-hospital initiation of sodium-glucose co-transporter-2 inhibitors in patients with acute heart failure

Timing of sodium–glucose cotransporter 2 inhibitor initiation and post‐discharge outcomes in acute heart failure with diabetes: A population‐based cohort study

Sodium-glucose co-transporter-2 inhibitors use in patients with reduced kidney function hospitalized for fluid overload and heart failure: an observational study

P471 CLINICAL AND THERAPEUTIC CHARACTERISTICS OF PATIENTS WITH HEART FAILURE IN THERAPY WITH SGLT2I RELATED TO THE HEART FAILURE OUTPATIENT

Real-world Use and Outcomes of Sodium-Glucose Cotransporter-2 Inhibitors in Adults With Diabetes and Heart Failure: A Population-level Cohort Study in Alberta, Canada

Use of Sodium-Glucose Cotransporter 2 Inhibitors in Hospitalized Patients

Abstract 11127: Effectiveness of Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Heart Failure With Preserved Ejection Fraction and Type 2 Diabetes

From Skepticism to Hope: The Evolving Concept of the Initiation and Use of Sodium-Glucose Cotransporter 2 Inhibitors in Hospitalized Patients

Real-life data on the tolerability of SGLT2 inhibitors in elderly patients with heart failure

Sodium-Glucose Cotransporter-2 (SGLT-2) Inhibitors Use among Heart Failure Patients and the Role of Pharmacists in Early Initiation of Therapy

Cardiovascular outcomes with sodium–glucose cotransporter-2 inhibitors vs other glucose-lowering drugs in 13 countries across three continents: analysis of CVD-REAL data

Effect of Sodium-Glucose Cotransporter 2 Inhibitors in Adults With Congenital Heart Disease

1230-P: Low Real-World Use of SGLT2 Inhibitors in People with Diabetes and Heart Failure—A Population Cohort Study

Sodium-Glucose Cotransporter 2 Inhibitors in South Australia: The Magic Before the Fame

Early Adoption of Sodium-Glucose Cotransporter-2 Inhibitor in Patients Hospitalized With Heart Failure With Mildly Reduced or Preserved Ejection Fraction

Uptake of sodium-glucose cotransporter-2 inhibitors in hospitalized patients with heart failure: insights from the veterans affairs healthcare system

Safety and Efficacy of Early SGLT2 Inhibitors Initiation in Diabetic Patients Following Acute Myocardial Infarction, a Retrospective Study

Inhibition Of Sodium-glucose Transport Protein As A Therapeutic Option In The Patients With Transthyretin Cardiac Amyloidosis

Quality Improvement Project To Study The Role Of A Cardiologist In Prescription Of Sglt2 Inhibitors In Patients With Heart Failure

SGLT ‐2 Inhibitor Use and Cause‐Specific Hospitalization Rates: An Outcome‐Wide Study to Identify Novel Associations of SGLT‐2 Inhibitors